In recent years, the number of patients with peripheral vascular disease in China has increased year-on-year. The vast clinical demand has created a broad market for peripheral interventional devices.
Easy-Flow (Chinese：畅德医疗), a peripheral interventional device developer, completed a tens of millions of CNY Angel funding round, led by Legend Capital (Chinese：君联资本), followed by Shanghai Xinyue Jiupeng Enterprise Consulting Center (Limited Partnership) (Chinese：上海心悦久朋企业咨询中心（有限合伙）). This round of financing will be used for Easy-Flow’s R&D of the peripheral interventional product pipeline.
Founded in 2021, Easy-Flow is committed to offering comprehensive product solutions in peripheral interventional devices and developing drug balloons, catheters, stents and thrombectomy devices for peripheral arteriovenous diseases.
The incidence of peripheral vascular disease in the over-60s is reported to be 10%, and the number of patients is expected to keep rising as China’s aging process accelerates. The substantial clinical demand makes peripheral vascular interventional devices likely to be the next market worth CNY 10 billion in the vascular interventional racetrack. According to Frost & Sullivan, the Chinese market for peripheral vascular interventional devices is expected to reach CNY 7.12 billion in 2022 and grow to CNY 30 billion in 2030.
However, due to the characteristic of peripheral vascular disease, the number of surgeries suitable for a single product in this field is limited, and the single-product market hardly supports a company’s long-term development. As a result, Easy-Flow has been working on building an integrated package of peripheral interventional products since its establishment, and several products will be submitted for registration or initiated into clinical practice by 2030.
Listed companies in the peripheral intervention field include Acotec (Chines: 先瑞达), Zylox-Tonbridge (Chinese：归创通桥), Endovastec™(Chinese：心脉医疗™), APT Medical(Chinese：惠泰医疗).